EyePoint Pharmaceuticals

NASDAQ EYPT
$14.01 2.13 17.93%
์˜ค๋Š˜ ์ฃผ๊ฐ€
๋ฏธ๊ตญ
๋ถ€๋ฌธ: ๋ณด๊ฑด ์˜๋ฃŒ ์‚ฐ์—…: ์ œ์•ฝ
์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

๋“ฑ๊ธ‰ ํ•€ ๋ฒ”์œ„

์ƒ‰์ธ: 38.75 %
Market cap ์‹œ๊ฐ€์ด์•ก โ€“ ํšŒ์‚ฌ์˜ ๋ชจ๋“  ์ฃผ์‹ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ์ด๋Š” ํŠน์ • ์ฃผ์‹์˜ ๊ฐ€๊ฒฉ์— ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋ฅผ ๊ณฑํ•˜์—ฌ ๊ณ„์‚ฐ๋ฉ๋‹ˆ๋‹ค.
378.14M
EV ๊ธฐ์—… ๊ฐ€์น˜๋Š” ํšŒ์‚ฌ์˜ ์ด ๊ฐ€์น˜๋ฅผ ์ธก์ •ํ•œ ๊ฒƒ์œผ๋กœ, ์ข…์ข… ์ฃผ์‹ ์‹œ๊ฐ€์ด์•ก์— ๋Œ€ํ•œ ๋ณด๋‹ค ํฌ๊ด„์ ์ธ ๋Œ€์•ˆ์œผ๋กœ ์‚ฌ์šฉ๋ฉ๋‹ˆ๋‹ค. ๊ธฐ์—… ๊ฐ€์น˜์—๋Š” ํšŒ์‚ฌ์˜ ์‹œ๊ฐ€์ด์•ก๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๋‹จ๊ธฐ ๋ฐ ์žฅ๊ธฐ ๋ถ€์ฑ„์™€ ํšŒ์‚ฌ ๋Œ€์ฐจ๋Œ€์กฐํ‘œ์˜ ํ˜„๊ธˆ๋„ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค.
294.75M
Beta ๋ฒ ํƒ€๋Š” ๊ฐ€์žฅ ๋„๋ฆฌ ์‚ฌ์šฉ๋˜๋Š” ์œ„ํ—˜ ์ง€ํ‘œ ์ค‘ ํ•˜๋‚˜์ด๋ฉฐ ํ†ต๊ณ„์  ์ฒ™๋„์ž…๋‹ˆ๋‹ค. ๋ถ„์„๊ฐ€๋“ค์€ ์ฃผ์‹์˜ ์œ„ํ—˜ ํ”„๋กœํ•„์„ ๊ฒฐ์ •ํ•ด์•ผ ํ•  ๋•Œ ์ด ์ฒ™๋„๋ฅผ ์ž์ฃผ ์‚ฌ์šฉํ•ฉ๋‹ˆ๋‹ค.
1.52
Shares ๋ฐœํ–‰ ์ฃผ์‹์ˆ˜๋Š” ๊ธฐ๊ด€ ํˆฌ์ž์ž๊ฐ€ ๋ณด์œ ํ•œ ์ฃผ์‹ ๋ธ”๋ก๊ณผ ํšŒ์‚ฌ ๋‚ด๋ถ€์ž๊ฐ€ ์†Œ์œ ํ•œ ์ œํ•œ๋œ ์ฃผ์‹์„ ํฌํ•จํ•˜์—ฌ ํ˜„์žฌ ๋ชจ๋“  ์ฃผ์ฃผ๊ฐ€ ๋ณด์œ ํ•˜๊ณ  ์žˆ๋Š” ํšŒ์‚ฌ์˜ ์ฃผ์‹์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.
69.77M
YTD ์—ฐ์ดˆ(YTD)๋Š” ๊ธˆ๋…„ ๋˜๋Š” ํšŒ๊ณ„์—ฐ๋„์˜ ์ฒซ๋‚ ๋ถ€ํ„ฐ ํ˜„์žฌ ๋‚ ์งœ๊นŒ์ง€์˜ ๊ธฐ๊ฐ„์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค. ๊ทธ ์•ฝ์–ด๋Š” ์ข…์ข… ํˆฌ์ž ์ˆ˜์ต ๋ฐ ๊ฐ€๊ฒฉ ๋ณ€ํ™”์™€ ๊ฐ™์€ ๊ฐœ๋…์„ ์ˆ˜์ •ํ•ฉ๋‹ˆ๋‹ค.
88.05 %

๋‹ค๊ฐ€์˜ค๋Š” ์ด๋ฒคํŠธ EyePoint Pharmaceuticals

๋ชจ๋“  ์ด๋ฒคํŠธ
์˜ˆ์ •๋œ ํ–ฅํ›„ ์ด๋ฒคํŠธ๊ฐ€ ์—†์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ฐจํŠธ EyePoint Pharmaceuticals

์ฃผ์‹๋ถ„์„ EyePoint Pharmaceuticals

์ง€์‹œ์ž ํšŒ์‚ฌ ์‚ฐ์—…
P/E (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ์— ๋Œ€ํ•œ ํˆฌ์ž์ž์˜ ํˆฌ์ž๊ฐ€ ๋ช‡ ๋…„ ๋™์•ˆ ์ด์ต์œผ๋กœ ๋ณด์ƒ๋˜๋Š”์ง€ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค.
-2.58 -1.50
P/BV (LTM) ํ˜„์žฌ ์žฅ๋ถ€๊ฐ€์น˜์— ๋Œ€ํ•œ ์ฃผ์‹์˜ ์‹œ์žฅ ๊ฐ€๊ฒฉ ๋น„์œจ์„ ํ‘œ์‹œํ•ฉ๋‹ˆ๋‹ค.
1.25 1.38
EV/EBITDA (LTM) ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํšŒ์‚ฌ ๊ฐ€์น˜์™€ ์„ธ์ „ EBITDA์˜ ๋น„์œจ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
-2.26 -0.54
Net Debt/EBITDA (LTM) ํšŒ์‚ฌ์˜ ๋ถ€์ฑ„ ๋น„์œจ์€ ํšŒ์‚ฌ๊ฐ€ ๋ถ€์ฑ„๋ฅผ ์ƒํ™˜ํ•˜๊ธฐ ์œ„ํ•ด ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํ˜„๊ธˆ ํ๋ฆ„์„ ์–ผ๋งˆ๋‚˜ ์˜ค๋žซ๋™์•ˆ ์šด์˜ํ•ด์•ผ ํ•˜๋Š”์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
0.64 0.35
ROE (LTM) ํšŒ์‚ฌ์˜ ์ฃผ์‹ ์ž๋ณธ ์‚ฌ์šฉ ํšจ์œจ์„ฑ์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค. ์ฆ‰, ROE๋Š” ์ง€๋‚œ 12๊ฐœ์›” ๋™์•ˆ ํˆฌ์žํ•œ ์ž๋ณธ์— ๋Œ€ํ•œ ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์ด ์–ผ๋งˆ์ธ์ง€๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
-49.19 -27.86

์—ฐ๊ฐ„ ๊ฐ€๊ฒฉ ๋ณ€๋™ EyePoint Pharmaceuticals

4.13$ 14.01$
์ตœ์†Œ ๋งฅ์Šค

์š”์•ฝ ๋ถ„์„ EyePoint Pharmaceuticals

์ ‘๊ทผ ๊ถŒํ•œ์„ ์–ป๋‹ค
Finrange ์ฃผ์‹ ๋“ฑ๊ธ‰์—
์ด ์š”๊ธˆ์ œ๋ฅผ ์ด์šฉํ•˜๋ฉด ์ œํ•œ ์—†์ด ์„œ๋น„์Šค๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ชจ๋“  ์ •๋ณด๋ฅผ ์ด์šฉํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์–ป๋‹ค 7์ผ ๋ฌด๋ฃŒ

์ฃผ์ฃผ๊ตฌ์กฐ EyePoint Pharmaceuticals

์ˆ˜์ต ๋ฐ ์ˆœ์ด์ต EyePoint Pharmaceuticals

๋ชจ๋“  ๋งค๊ฐœ๋ณ€์ˆ˜

ํšŒ์‚ฌ์†Œ๊ฐœ EyePoint Pharmaceuticals

์ œ์•ฝํšŒ์‚ฌ์ธ EyePoint Pharmaceuticals, Inc.๋Š” ๋ฏธ๊ตญ, ์ค‘๊ตญ ๋ฐ ์˜๊ตญ์—์„œ ์•ˆ๊ณผ ์งˆํ™˜ ์น˜๋ฃŒ์šฉ ์•ˆ๊ณผ์šฉ ์ œํ’ˆ์„ ๊ฐœ๋ฐœ ๋ฐ ์ƒ์šฉํ™”ํ•ฉ๋‹ˆ๋‹ค. ์ด ํšŒ์‚ฌ๋Š” ๋‹น๋‡จ๋ณ‘์„ฑ ํ™ฉ๋ฐ˜๋ถ€์ข… ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ์ฃผ์‚ฌ ๊ฐ€๋Šฅํ•œ ์„œ๋ฐฉ์„ฑ ๋งˆ์ดํฌ๋กœ ์ธ์„œํŠธ์ธ ILUVIEN์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋ˆˆ์˜ ํ›„๋ถ€์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๋งŒ์„ฑ ๋น„๊ฐ์—ผ์„ฑ ํฌ๋„๋ง‰์—ผ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ์œ ๋ฆฌ์ฒด๊ฐ•๋‚ด ์ฃผ์‚ฌ์šฉ ํ”Œ๋ฃจ์˜ค์‹œ๋†€๋ก  ์•„์„ธํ† ๋‚˜์ด๋“œ ์œ ๋ฆฌ์ฒด๊ฐ•๋‚ด ์ž„ํ”Œ๋ž€ํŠธ์ธ YUTIQ; ๋ฐ ๋ฐฑ๋‚ด์žฅ ์ˆ˜์ˆ  ํ›„ ์น˜๋ฃŒ๋ฅผ ํฌํ•จํ•˜์—ฌ ์ˆ˜์ˆ  ํ›„ ์•ˆ๊ตฌ ์—ผ์ฆ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ๋ฑ์‚ฌ๋ฉ”ํƒ€์† ์•ˆ๋‚ด ํ˜„ํƒ์•ก์ธ DEXYCU. ๋˜ํ•œ ์Šต์„ฑ ์—ฐ๋ น ๊ด€๋ จ ํ™ฉ๋ฐ˜๋ณ€์„ฑ, ๋‹น๋‡จ๋ณ‘์„ฑ ๋ง๋ง‰๋ณ‘์ฆ ๋ฐ ๋ง๋ง‰ ์ •๋งฅ ํ์‡„์ฆ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ 1์ƒ ์ž„์ƒ ์‹œํ—˜ ์ค‘์ธ ํ‹ฐ๋กœ์‹  ํ‚ค๋‚˜์ œ ์–ต์ œ์ œ์˜ 1๋…„์— 2ํšŒ ์ƒ๋ถ„ํ•ด์„ฑ ์ œ์ œ์ธ EYP-1901์„ ๊ฐœ๋ฐœ ์ค‘์ž…๋‹ˆ๋‹ค. ๋ฐ ๋ˆˆ์˜ ํ›„๋ถ€์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๋งŒ์„ฑ ๋น„๊ฐ์—ผ์„ฑ ํฌ๋„๋ง‰์—ผ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ YUTIQ50. ์ด ํšŒ์‚ฌ๋Š” Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics ๋ฐ Equinox Science, LLC์™€ ์ „๋žต์  ํ˜‘๋ ฅ ๊ด€๊ณ„๋ฅผ ๋งบ๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ๋˜ํ•œ ์•ˆ๊ณผ ์ˆ˜์ˆ  ํ›„ ์ˆ˜์ˆ  ํ›„ ์—ผ์ฆ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ DEXYCU์˜ ๊ณต๋™ ํ”„๋กœ๋ชจ์…˜์„ ์œ„ํ•ด ImprimisRx PA, Inc.์™€ ์ƒ์—…์  ์ œํœด๋ฅผ ๋งบ์—ˆ์Šต๋‹ˆ๋‹ค. ์ด ํšŒ์‚ฌ๋Š” ์ด์ „์— pSivida Corp.๋กœ ์•Œ๋ ค์กŒ์œผ๋ฉฐ 2018๋…„ 3์›”์— EyePoint Pharmaceuticals, Inc.๋กœ ์ด๋ฆ„์„ ๋ณ€๊ฒฝํ–ˆ์Šต๋‹ˆ๋‹ค. EyePoint Pharmaceuticals, Inc.๋Š” 1987๋…„์— ์„ค๋ฆฝ๋˜์—ˆ์œผ๋ฉฐ ๋งค์‚ฌ์ถ”์„ธ์ธ  ์ฃผ ์›Œํ„ฐํƒ€์šด์— ๋ณธ์‚ฌ๋ฅผ ๋‘๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์ฃผ์†Œ:
480 Pleasant Street, Watertown, MA, United States, 02472
ํšŒ์‚ฌ ์ด๋ฆ„: EyePoint Pharmaceuticals
๋ฐœํ–‰์ž ํ‹ฐ์ปค: EYPT
ISIN: US30233G2093
๊ตญ๊ฐ€: ๋ฏธ๊ตญ
๊ตํ™˜: NASDAQ
ํ†ตํ™”: $
IPO ๋‚ ์งœ: 2005-01-27
์‚ฐ์—…: ์ œ์•ฝ
๋Œ€์ง€: https://eyepointpharma.com